retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Eli Lilly's shows promising weight loss results in 3 Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor

GLP-1, or glucagon-like peptide-1, is a hormone that plays a significant role in regulating appetite and glucose metabolism

Author Contributions All authors reviewed, edited, and approved the final version of the manuscript

Clinical trials have shown that these medications reduce the risk of major cardiovascular events, including heart attack and stroke

2021 Jul 17;398(10296):212 )

The concept underlying these unimolecular multi-agonists is that a single molecule with complementary signaling through more than one receptor, each of which offers beneficial effects on systems metabolism, would maximize metabolic outcomes at tolerable doses

The intervention group consisted of patients who were prescribed GLP-1 RA medications, including Victoza (Liraglutide 1.8 mg), Saxenda (Liraglutide 3 mg), Ozempic (Semaglutide 1 mg), and Wegovy (Semaglutide 2.4 mg)